Dalpiciclib after surgery for early breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a pill called dalpiciclib, a CDK4/6 inhibitor, given after surgery to lower the risk of breast cancer returning. It's for women with hormone-positive, HER2-negative early-stage breast cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- You have early-stage breast cancer that is hormone receptor-positive (fueled by estrogen or progesterone) and HER2-negative (a certain growth protein).
- Your tumor is stage II or III, meaning it has not spread to distant parts of the body.
- You have had surgery to remove the cancer within the last 12 months.
- If you had chemotherapy or radiation, you've recovered from side effects and enough time has passed (at least 21 days for chemo, 14 days for radiation).
- You are generally healthy, with good heart, liver, kidney, and blood function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new pill (dalpiciclib) combined with hormone therapy for women with early-stage, hormone receptor positive/HER2-negative breast cancer. The goal is to see if this combination can lower the chance of cancer coming back after surgery.
This study tests whether adding a new drug called dalpiciclib to standard hormone therapy improves outcomes for women with early-stage breast cancer that is hormone-receptor positive. The goal is to see if this combination is more effective and safe than hormone therapy alone.
This trial tests whether adding the drug dalpiciclib to standard hormone therapy improves outcomes for people with a certain type of early breast cancer (hormone receptor-positive, HER2-negative). It may help lower the risk of the cancer coming back.
This study tests a new combination of two medications given before surgery for stage II-III hormone-positive, HER2-negative breast cancer. The goal is to see if this approach can shrink tumors and improve outcomes, possibly making surgery more successful.
This trial studies whether dalpiciclib can slow down or control advanced hormone receptor–positive breast cancer and assess how safe it is. It’s for people whose cancer has come back in a limited way or spread and can’t be fully cured with surgery or radiation.
This trial tests a combination of three drugs—dalpiciclib (a new cell-cycle inhibitor), anti-HER2 therapy, and hormone therapy—for advanced breast cancer that is positive for both hormone receptors and HER2 protein. The goal is to help patients whose cancer has responded to initial treatment stay in remission longer.
Hear when a new Early Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.